If you have been following the GLP-1 medication landscape over the last two years, you have watched a genuinely complicated regulatory story unfold in real time — shortage declarations, court cases, enforcement deadlines, manufacturer price cuts, and a compounding pharmacy industry that went from explosive growth to a much more constrained operating environment.
This guide explains where things stand as of May 2026, without hype in either direction. Compounded GLP-1s are not gone — but they are no longer widely available the way they were in 2023 and 2024. The brands are not the only option — but they have gotten meaningfully more affordable. Your situation, your medical history, and your relationship with a licensed clinician determine which path makes sense for you. This guide gives you the framework to have that conversation intelligently.
A Quick GLP-1 Primer
GLP-1 receptor agonists are medications that mimic a naturally occurring gut hormone — glucagon-like peptide-1 — that is released after eating and signals the brain to reduce appetite, the pancreas to release insulin, and the stomach to slow gastric emptying. The result is reduced caloric intake, improved glycemic control, and in clinical trials, meaningful and sustained weight loss.
Semaglutide (Novo Nordisk)
- Ozempic — subcutaneous injection, type 2 diabetes, FDA NDA 209637, approved 2017
- Wegovy — subcutaneous injection, chronic weight management at 2.4 mg, FDA NDA 215256, approved 2021
- Rybelsus — oral tablet, type 2 diabetes
Tirzepatide (Eli Lilly)
A dual GIP/GLP-1 receptor agonist — the first approved medication to activate both the GLP-1 receptor and the GIP receptor simultaneously. This dual mechanism appears to produce greater average weight loss than GLP-1 agonism alone.
- Mounjaro — subcutaneous injection, type 2 diabetes, approved 2022
- Zepbound — subcutaneous injection, chronic weight management, approved 2023
The landmark clinical data behind these agents is substantial. In the STEP 1 trial (Wilding et al., 2021, PMID: 33567185), semaglutide 2.4 mg produced a mean 14.9% body weight reduction over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., 2022, PMID: 35658024) showed tirzepatide 15 mg produced a mean 20.9% weight loss over 72 weeks. The SELECT trial (Lincoff et al., 2023, PMID: 37952131) demonstrated that semaglutide reduced major cardiovascular events by 20% in non-diabetic patients with obesity and established cardiovascular disease.
The Shortage Timeline: How We Got Here
December 2022 — The Shortages Begin
Explosive demand for GLP-1 medications — driven by clinical evidence, celebrity attention, and social media — created supply shortfalls that Novo Nordisk and Eli Lilly could not immediately meet. Both semaglutide and tirzepatide were placed on the FDA's drug shortage list. Under Section 503A and 503B of the FD&C Act, compounding pharmacies may compound drugs on the FDA shortage list, even if those drugs would otherwise be considered "essentially copies" of commercially available products. This opened the door for widespread compounding of semaglutide and tirzepatide as a legal, patient-access solution.
2023–2024 — The Compounding Era
During the shortage period, a large ecosystem of compounding pharmacies — both 503A state-licensed pharmacies and 503B outsourcing facilities — began producing and dispensing compounded semaglutide and tirzepatide at a fraction of the brand-name cost. This also generated concerns. The FDA issued a safety alert in June 2024 flagging that some compounders were using semaglutide salt forms — semaglutide sodium and semaglutide acetate — rather than the semaglutide base used in approved products. These are different chemical entities.
October/December 2024 — Shortage Resolutions Begin
The FDA declared the tirzepatide shortage resolved on December 19, 2024, citing Eli Lilly's restored manufacturing capacity. The agency's timeline required 503A pharmacies to cease compounding copies by February 18, 2025, and 503B outsourcing facilities by March 19, 2025.
February–April 2025 — Semaglutide Follows
The FDA declared the semaglutide shortage resolved on February 21, 2025. (FDA Drug Alerts and Statements, February 21, 2025) The agency established enforcement discretion periods:
- 503A state-licensed pharmacies: cease compounding copies by April 22, 2025
- 503B outsourcing facilities: cease compounding copies by May 22, 2025
The compounding industry challenged these timelines in federal court. Both cases failed. The Outsourcing Facilities Association v. FDA semaglutide case was denied at the preliminary injunction stage on April 24, 2025. Enforcement discretion periods expired as scheduled.
April 30, 2026 — FDA Proposes to Close the Final 503B Door
On April 30, 2026, the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list. As Orrick LLP's legal analysis (May 2026) confirmed, this proposal "does not directly alter the legal framework for 503A compounding pharmacies." The public comment period closes June 29, 2026.
What "Compounded" Actually Means: 503A vs. 503B
503A compounding pharmacies are state-licensed pharmacies that prepare medications for individual patients on a prescription-by-prescription basis. Key features:
- Requires a valid prescription for an identified individual patient
- Regulated primarily by state boards of pharmacy
- Must follow USP <797> standards for sterile preparations and USP <795> for non-sterile
- Cannot produce large batch volumes; limited to individual or limited anticipatory quantities
- Source: FDA Section 503A
503B outsourcing facilities are FDA-registered manufacturers that compound medications in large batches, primarily for distribution to healthcare facilities without requiring individual patient prescriptions. They are held to current Good Manufacturing Practice (cGMP) standards. Post-shortage, 503B facilities must no longer produce essentially-equivalent copies. 503A pharmacies retain a narrow legal pathway under specific conditions.
When Compounded GLP-1s Are Now Legal (2026)
As of May 2026, three categories of individualized need remain viable under 503A:
1. Documented allergy or intolerance to a brand product excipient. Wegovy and Ozempic contain inactive excipients including disodium phosphate dihydrate, propylene glycol, and phenol. A patient with a documented, clinically verified allergy or intolerance to one of these specific excipients — confirmed through allergy testing or prior adverse reaction documentation — may have a legitimate basis for a compounded formulation. This requires written prescriber documentation and chart evidence.
2. Need for a dose strength not commercially available. Some patients may have clinical needs for non-standard dose strengths — for example, a very low starting dose for a patient with a history of severe GI intolerance. The prescriber must document the specific clinical rationale.
3. A clinically justified combination product. However, the FDA's April 1, 2026 policy reminder was explicit: a semaglutide/B12 combination may still be considered essentially a copy if both the semaglutide and B12 amounts fall within 10% of commercially available counterparts. The clinical difference must be prescriber-documented and individualized.
When Compounded GLP-1s Are NOT Legal
The following are not sufficient justifications for 503A compounding under current law:
- Cost savings. Patient preference for a cheaper medication does not constitute a "significant difference" for that patient under the essentially-a-copy standard. The FDA has stated this clearly.
- General population demand. 503A compounding cannot be used to produce a drug in "inordinate amounts" essentially equivalent to a commercially available product. The shortage made this temporarily permissible. The shortage is over.
- Pure copy at standard dose. A compounded semaglutide vial at the same concentration and dose as Wegovy, even with B12 added at standard vitamin concentrations, is likely an essentially-equivalent copy under current FDA guidance.
Programs that continue to offer compounded GLP-1s to any patient, at standard doses, for cost savings, without individual clinical documentation, are operating outside the current regulatory framework. Novo Nordisk has filed over 130 federal lawsuits against such programs as of February 2026.
The Cost Question
Cost has been the central driver for most patients considering compounded GLP-1s. Here is an honest assessment of where prices stand in May 2026.
| Product | Type | Typical Self-Pay (Monthly) |
|---|---|---|
| Wegovy (semaglutide, weight) | Brand, FDA-approved | $349–$499 via NovoCare Direct; list ~$1,349 (dropping to ~$675 in 2027) |
| Ozempic (semaglutide, diabetes) | Brand, FDA-approved | $349–$499 via NovoCare Direct; list ~$1,028 |
| Zepbound (tirzepatide, weight) | Brand, FDA-approved | $299–$449 via LillyDirect |
| Mounjaro (tirzepatide, diabetes) | Brand, FDA-approved | ~$1,086 list price; covered for T2D with prior auth |
| Compounded semaglutide (503A) | Not FDA-approved; 503A only | ~$149–$299 where legally available |
| Compounded tirzepatide (503A) | Not FDA-approved; 503A only | ~$299–$347 where legally available |
Sources: CNN on Novo Nordisk direct pricing (February 2026); LillyDirect Zepbound pricing (January 2026); IvyRx compounded pricing guide (January 2026).
Novo Nordisk launched NovoCare Direct, offering Wegovy at $349/month for eligible self-pay patients. List prices for Wegovy and Ozempic are announced to drop to approximately $675/month effective January 1, 2027. Before assuming compounded is the only affordable option, discuss with your prescribing clinician whether manufacturer assistance programs, insurance pathways, or formulary alternatives are accessible to you.
Safety Considerations
Compounded medications and brand-name medications share the same active molecule when correctly prepared. But they do not share the same safety floor — and that distinction matters.
Brand-name products
- Produced under FDA current Good Manufacturing Practice (cGMP) standards
- Pre-market safety and efficacy review via full clinical trial programs
- Mandatory adverse event reporting to FDA's FAERS system
- Prefilled autoinjector pens with standardized doses — reducing dosing error risk
- Active post-market pharmacovigilance
Compounded products (503A)
- Produced under USP <797> sterile compounding standards, regulated by state boards of pharmacy
- No pre-market FDA safety and efficacy review
- Adverse event reporting to FDA is voluntary — likely resulting in underreporting
- Multi-dose vials requiring patient self-measurement — higher dosing error risk
- Quality depends heavily on individual pharmacy practices and API sourcing
A 2025–2026 study in Expert Opinion on Drug Safety (PMID: 40285721; Liu et al.) analyzed 81,078 GLP-1 adverse event reports in FAERS. Compared to non-compounded formulations, compounded GLP-1 products showed significantly elevated reporting odds ratios for preparation errors (ROR 48.92), contamination events (ROR 19.00), hospitalization (ROR 2.35), and compounding/manufacturing issues (ROR 8.51).
A separate narrative review in the American Journal of Managed Care (PMID: 40966636) concluded that compounded semaglutide products "may lack the quality controls historically seen with compounded formulations, resulting in risks for dosing errors and adverse health outcomes."
The salt form alert. The FDA has specifically flagged that semaglutide sodium and semaglutide acetate — salt forms sometimes used in compounded products — are different chemical entities from the semaglutide base used in Ozempic and Wegovy. Patients and clinicians should confirm the chemical form in any compounded semaglutide product.
A Brookings Institution analysis (April 2025) found that because no external reference standard exists for compounding-grade bulk semaglutide, some manufacturers allow up to 15% of a batch to consist of materials other than semaglutide, without requiring testing for heavy metals or residual solvents. Legitimate 503A pharmacies sourcing from FDA-registered suppliers with verified COAs are substantially different — but the variance in the market means pharmacy selection matters enormously.
How to Know If Compounded Is Appropriate for You
These are the questions to work through with your prescribing clinician before pursuing compounded semaglutide or tirzepatide in 2026.
1. Do I have a documented allergy or intolerance to any inactive ingredient in the brand product? Ask your clinician to verify whether phenol, propylene glycol, or disodium phosphate dihydrate sensitivities are in your chart with enough specificity to support a 503A prescription.
2. Does my clinical situation require a dose that isn't commercially available? If you have a history of severe GI intolerance to standard titration schedules, discuss whether a non-standard starting dose constitutes a genuine medical necessity that the prescriber can document.
3. Can you document the specific clinical rationale for compounding in my chart? For a compounded prescription to be legally defensible under 503A, the prescriber's determination must be documented.
4. Have I explored brand-name direct-pay programs? Verify whether you qualify for manufacturer savings programs or any insurance coverage pathway before concluding that compounded is the only affordable option.
5. Which state-licensed, USP <797>-compliant pharmacy would dispense the medication? Ask your clinician to name the specific pharmacy and confirm it is verifiable through your state's pharmacy licensing board.
6. What is the monitoring plan? Any legitimate program should include defined check-in intervals and a protocol for managing adverse effects or dose adjustments.
Red Flags for Compounded Peptide Programs
- No valid prescription required. Any provider or platform offering GLP-1 compounds without a genuine clinical evaluation is not operating legally.
- "Research chemical" labeling. Semaglutide or tirzepatide sold as a "research chemical" has no lawful basis for human administration under any framework.
- No pharmacy identified. A program that ships medication but will not name the dispensing pharmacy, cannot confirm state licensure, and will not provide a COA is not a regulated clinical program.
- Cold-chain violations. Injectable GLP-1 compounds require refrigeration. Product arriving warm, without ice packs, or with inadequate cold-chain handling has compromised integrity.
- Implausibly low pricing. Legitimate sterile compounding under USP <797> has a cost floor. Very-low-price offers are a warning sign.
- Salt form products. If you are told your compounded semaglutide is "semaglutide sodium" or "semaglutide acetate," the FDA has explicitly flagged these as different chemical entities from the approved drug.
What to Look for in a Legitimate Compounded GLP-1 Program
Where compounded GLP-1 therapy is clinically appropriate and legally sound, a well-run program looks like this:
- Named, licensed prescriber. You interact with a specific licensed provider whose credentials are verifiable through their state licensing board.
- Individual clinical evaluation. The prescriber has reviewed your medical history and documented a specific clinical rationale for compounding rather than brand-name therapy.
- Named, state-licensed 503A pharmacy. The dispensing pharmacy is identified, licensure is verifiable, and the pharmacy operates under USP <797> for injectable preparation.
- Certificate of Analysis available. The pharmacy can provide a batch-specific COA confirming semaglutide base identity, purity, and sterility testing. API is from an FDA-registered supplier.
- Monitoring and follow-up built in. The program includes defined check-ins, lab monitoring where appropriate, and a clear process for managing concerns.
- Compliant language. The program does not promise specific outcomes and does not market compounding as universally preferable to brand-name therapy.
Frequently Asked Questions
Is compounded semaglutide still legal in 2026?
Yes, but only under specific, documented conditions. The broad shortage-based authorization ended when the FDA declared the semaglutide shortage resolved in February 2025 and enforcement discretion periods expired in April–May 2025. What remains legal is 503A compounding of a semaglutide formulation that is not essentially a copy of the brand — where the prescriber has documented, for an identified individual patient, a specific clinical need for a meaningfully different formulation (due to excipient allergy, a non-commercially-available dose, or a clinically justified combination). Cost savings and patient preference alone are not qualifying reasons under current federal law.
How is compounded tirzepatide different from Zepbound or Mounjaro?
The active molecule is the same when correctly compounded from tirzepatide base. The differences are: compounded tirzepatide is not FDA-approved; it is not manufactured under cGMP standards; it is dispensed from a multi-dose vial rather than a prefilled autoinjector pen; it may include additional ingredients not present in the brand; and it requires a documented clinical justification that goes beyond cost savings. The shortage that made widespread compounding legal ended December 2024 for tirzepatide.
Why did some companies stop offering compounded GLP-1s?
Following the FDA's shortage resolution determinations and the expiration of enforcement discretion periods in early 2025, companies that had built models around compounding essentially-equivalent GLP-1 copies were no longer operating legally. Novo Nordisk filed over 130 lawsuits against telehealth platforms and pharmacies it alleges continued beyond the deadline. Hims & Hers, for example, ceased its compounded semaglutide offering after Novo Nordisk filed suit in February 2026.
Does adding B12 to semaglutide make it legally different?
Not automatically. The FDA's April 1, 2026 policy reminder addressed this directly: a combination of semaglutide plus B12 may still be considered essentially a copy if both the semaglutide and B12 amounts fall within 10% of commercially available counterparts, through the same route of administration. The clinical and legal difference must be prescriber-documented and individualized — not a blanket practice of adding B12 to all patients' compounded semaglutide.
Are the side effects of compounded semaglutide the same as Wegovy?
When correctly compounded from semaglutide base (not a salt form), the expected class-effect side effects — nausea, vomiting, diarrhea, constipation, injection site reactions — are the same, because the active molecule is the same. However, compounded products carry additional risk categories: elevated dosing error risk from multi-dose vials compared to prefilled pens; higher contamination risk if sterility standards were substandard; and adverse events tied to incorrect chemical form (salt forms). The pharmacovigilance data (PMID: 40285721) show compounded GLP-1 formulations are associated with 2.35× higher hospitalization odds compared to brand-name products. Discuss these tradeoffs explicitly with your prescribing clinician.
What is the FDA's 503B bulks list proposal, and does it affect me?
On April 30, 2026, the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that 503B outsourcing facilities may compound. This primarily affects large-scale manufacturers that had already ceased operations after the shortage resolution. It does not directly alter the 503A framework for state-licensed compounding pharmacies serving individual patients, as Orrick LLP has confirmed. The public comment period closes June 29, 2026.
How do I verify a compounding pharmacy is legitimate?
Take these concrete steps: (1) Check active license through your state Board of Pharmacy online database. (2) Search the NABP database for accreditation status. (3) Ask for the batch Certificate of Analysis confirming semaglutide base identity, purity ≥97%, and sterility testing results. (4) Confirm the API source is an FDA-registered supplier. (5) Search FDA.gov for any warning letters against the pharmacy. (6) Confirm the medication is being prepared under USP <797> sterile compounding standards, with cold-chain shipping.
What happens if I need to transition from compounded to brand-name?
Transitioning from a compounded GLP-1 formulation to a brand-name product primarily involves logistical and dosing considerations that your prescribing clinician should manage. Dose conversion may require adjustment. Timing the transition to avoid gaps in therapy matters clinically, as discontinuation can lead to appetite rebound and weight regain (as demonstrated in SURMOUNT-4, JAMA 2023). Your clinician should initiate the conversation about transitioning before regulatory or access changes force an abrupt switch. Do not abruptly stop therapy without clinician guidance.
Informational only. This content is educational and does not constitute medical advice. It does not establish a patient-clinician relationship. Individual medication decisions should be made in consultation with a licensed healthcare provider who has reviewed your complete medical history.
Primary sources: FDA GLP-1 Compounding Policy Page · FDA 503B Bulks List Proposal, April 30, 2026 · FDA GLP-1 Unapproved Drug Safety Concerns · FDA 503A Essentially a Copy Guidance · Liu et al., Expert Opinion on Drug Safety 2026, PMID:40285721 · Am J Manag Care, PMID:40966636 · Wilding et al., STEP 1, PMID:33567185 · Jastreboff et al., SURMOUNT-1, PMID:35658024 · Lincoff et al., SELECT, PMID:37952131 · Orrick LLP Analysis, May 2026 · CNN Novo Nordisk Pricing · Brookings GLP-1 Analysis